TyrNovo Overview

  • Year Founded
  • 2005

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • 2ndary - Private

  • Latest Deal Amount
  • $1.65M

TyrNovo General Information

Description

Developer of small molecular drugs designed to treat cancer and inflammation diseases. The company's small molecular drugs are used for the treatment for several neuro degenerative conditions that result from acute events, such as stroke, traumatic brain injury, nerve agents exposure and open heart surgery, glaucoma, enabling patients to begin treatment more quickly and result in a higher likelihood of a successful treatment.

Contact Information

Formerly Known As
NovoTyr Therapeutics
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 8 Abba Eban Avenue
  • Herzliya 46723
  • Israel
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Acquirer
Vertical(s)
Corporate Office
  • 8 Abba Eban Avenue
  • Herzliya 46723
  • Israel

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

TyrNovo Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Secondary Transaction - Private 06-Oct-2017 $1.65M Completed Generating Revenue
4. Merger/Acquisition 06-Oct-2017 Completed Generating Revenue
3. Accelerator/Incubator 19-Mar-2013 Completed Startup
2. Early Stage VC 18-Jun-2008 $1M $1M Completed Startup
1. Seed Round Completed Startup
To view TyrNovo’s complete valuation and funding history, request access »

TyrNovo Patents

TyrNovo Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3236225-A1 Isolated trans isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-n-(3,4,5-trihydroxy-benzyl)-thioacrylamide Pending 04-Nov-2021
EP-4426278-A1 Isolated trans isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-n-(3,4,5-trihydroxy-benzyl)-thioacrylamide Pending 04-Nov-2021
EP-4426278-A4 Isolated trans isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-n-(3,4,5-trihydroxy-benzyl)-thioacrylamide Pending 04-Nov-2021
US-20240425452-A1 Isolated trans isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-n-(3,4,5-trihydroxy-benzyl)-thioacrylamide Pending 04-Nov-2021
WO-2023079545-A1 Isolated trans isomer of 3-(2-bromo-3,4-dihydroxy-phenyl)-n-(3,4,5-trihydroxy-benzyl)-thioacrylamide Inactive 04-Nov-2021 C07C327/44
To view TyrNovo’s complete patent history, request access »

TyrNovo Former Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Biomedix Incubator Accelerator/Incubator Minority
Gefen Biomed Investments Venture Capital Minority
Goldman Hirsh Partner Corporation Minority
Meytav Technological Incubator Accelerator/Incubator Minority
Orot Luces Impact Investing Minority
You’re viewing 5 of 6 investors. Get the full list »

TyrNovo FAQs

  • When was TyrNovo founded?

    TyrNovo was founded in 2005.

  • Where is TyrNovo headquartered?

    TyrNovo is headquartered in Herzliya, Israel.

  • What industry is TyrNovo in?

    TyrNovo’s primary industry is Drug Discovery.

  • Is TyrNovo a private or public company?

    TyrNovo is a Private company.

  • What is the current valuation of TyrNovo?

    The current valuation of TyrNovo is .

  • What is TyrNovo’s current revenue?

    The current revenue for TyrNovo is .

  • How much funding has TyrNovo raised over time?

    TyrNovo has raised $1M.

  • Who are TyrNovo’s investors?

    Biomedix Incubator, Gefen Biomed Investments, Goldman Hirsh Partner, Meytav Technological Incubator, and Orot Luces are 5 of 6 investors who have invested in TyrNovo.

  • When was TyrNovo acquired?

    TyrNovo was acquired on 06-Oct-2017.

  • Who acquired TyrNovo?

    TyrNovo was acquired by Purple Biotech.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process